Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast]

References

• Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792–1799. doi:10.1111/jdv.14386
   PubMed Web of Science ®Google Scholar
• Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42. doi:10.2147/PTT.S181808
   PubMed Web of Science ®Google Scholar
• Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13–19. doi:10.1007/s40257-021-00655-y
   PubMed Web of Science ®Google Scholar
• Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669–673.
   PubMed Web of Science ®Google Scholar
• Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–684. doi:10.1111/ijd.12070
   PubMed Web of Science ®Google Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131–144. doi:10.2147/PTT.S98954
   PubMed Web of Science ®Google Scholar
• Prinz JC, Choon SE, Griffiths CEM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2023;37(2):256–273. doi:10.1111/jdv.18720
   PubMed Web of Science ®Google Scholar
• Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical disease measures in generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):39–50. doi:10.1007/s40257-021-00653-0
   PubMed Web of Science ®Google Scholar
• Burden AD, Bissonnette R, Lebwohl MG, et al. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). J Eur Acad Dermatol Venereol. 2023;37(7):1327–1335. doi:10.1111/jdv.18999
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279–288. doi:10.1016/j.jaad.2011.01.032
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235–1270. doi:10.1111/1346-8138.14523
   PubMed Web of Science ®Google Scholar
• Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1). J Eur Acad Dermatol Venereol. 2020;34(8):1654–1665. doi:10.1111/jdv.16684
   PubMed Web of Science ®Google Scholar
• Fujita H, Gooderham M, Romiti R. Diagnosis of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):31–38. doi:10.1007/s40257-021-00652-1
   PubMed Web of Science ®Google Scholar
• Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37(4):737–752. doi:10.1111/jdv.18851
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. FDA approves the first treatment option for generalized pustular psoriasis flares in adults. (September 01, 2022) Available at: https://www.boehringer-ingelheim.us/press-release/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults. Accessed July 20, 2023.
   Google Scholar
• Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51–64. doi:10.1007/s40257-021-00658-9
   PubMed Web of Science ®Google Scholar
• Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17(9):1–13.
   Web of Science ®Google Scholar
• Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033–1047. doi:10.1080/1744666X.2022.2116003
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) summary of positive opinion: Spevigo (spesolimab). (2022). Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/spevigo. Accessed July 20, 2023.
   Google Scholar
• Boehringer Ingelheim. SPEVIGO prescribing information. (September 2022) Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf. Accessed July 20, 2023.
   Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981–983. doi:10.1056/NEJMc1811317
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431–2440. doi:10.1056/NEJMoa2111563
   PubMed Web of Science ®Google Scholar
• Shao S, Wang G. Commentary on a clinical trial of spesolimab, a humanized anti-interleukin-36 receptor monoclonal antibody, in generalized pustular psoriasis. Dermatol Ther (Heidelb). 2022;12(12):2627–2635. doi:10.1007/s13555-022-00830-x
   PubMed Web of Science ®Google Scholar
• Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalized pustular psoriasis flares (Effisayil 2): a multicenter, randomized, placebo-controlled trial. Lancet. 2023 (e-pub, September 19). doi:10.1016/S0140-6736(23)01378-8
   PubMed Web of Science ®Google Scholar
• Gudjonsson JE, Reich A, Barker JN, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody, in the treatment of generalized pustular psoriasis: results from a Phase 2 trial. Presented at: 30th EADV Congress; 29 September–2 October 2021. (Virtual).
   Google Scholar
• Gudjonsson J, Randazzo B, Zhou J, Peterson R, Lizzul P. Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: design of a pivotal Phase 3 clinical trial and a long-term extension study. Presented at: the 2022 Annual Meeting of the American Academy of Dermatology (AAD); Boston, MA, US; March 25–29, 2022. Abstract/Poster 34617.
   Google Scholar